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Angiogenesis research investigates the formation of new blood vessels in wound healing, tumour growth and embryonic
development. Circulating, bone marrow-derived endothelial progenitor cells (EPCs) were first described 8 years ago, yet the exact
nature of these endothelial precursor cells remains unclear. The contributions of circulating EPCs to angiogenesis in tumours,
ischaemic injury and other diseases as well as their usefulness in the repair of wounded hearts and limbs remain under intense
investigation.
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The growth of new blood vessels, or neovascularisation, is required
for embryonic development and stimulates the healing of injured
tissues, but also promotes tumour growth and inflammatory
diseases. Quiescent vascular and lymphatic endothelial cells are
activated by proangiogenic growth factors such as vascular
endothelial growth factor (VEGF), which stimulate endothelial cell
proliferation and migration, thereby promoting new vessel
formation (Stacker et al, 2002; Jin and Varner, 2004). Thirty years
of analysis has revealed many of the mechanisms driving blood
vessel sprouting. However, in 1997, the study of vascular
development was changed when Dr Jeffrey Isner and his research
team at Tufts University first described circulating, bone marrow-
derived endothelial progenitor cells (EPCs) (Asahara et al, 1997).
In the 8 years since, mounting evidence has shown that endothelial
cells can arise from circulating bone marrow-derived cells. Human
bone marrow-derived cells have been shown to infiltrate human
tumours (Peters et al, 2005) and to give rise to up to 16% of the
tumour neovasculature in a normal mouse (Ruzinova et al, 2003).
However, controversies about the phenotype of this circulating
progenitor cell have not completely resolved which circulating cells
give rise to endothelial cells during in vivo angiogenesis (Figure 1).
INITIAL CHARACTERISATION OF EPCs
Circulating EPCs were first identified as a population of postnatal
mononuclear blood cells that adopted an adherent, endothelial
morphology when cultured for 7 days in endothelial growth
medium (Asahara et al, 1997). These initial studies showed that a
CD34-enriched (15% CD34þ) subpopulation of mononuclear
blood cells formed blood island-like colonies on fibronectin-coated
culture plates. CD34 is a marker of haematopoietic stem cells and
is expressed by 0.1% of circulating mononuclear cells. Like
endothelial cells, these isolated cells incorporated acetylated DiI,
expressed several markers in common with endothelial cells such
as CD34, CD31, vascular endothelial growth factor receptor 2
(VEGFR2) and Tie2. A small percentage of labelled human EPCs
were able to incorporate into blood vessels in athymic nude mice
in which hindlimb ischaemia was induced in vivo. Murine b-
galactosidaseþEPCs and rabbit EPCs also incorporated into blood
vessels in ischaemic tissue (Asahara et al, 1997). Further studies in
mice transplanted with b-galactosidaseþ(LacZþ) bone marrow
showed clearly that bone marrow-derived cells naturally partici-
pate in the formation of new blood vessels in ischaemic limb
(Asahara et al, 1999) and ischaemic heart. These transplanted cells
improved blood flow in animals with hindlimb ischaemia. Further
analysis of these cells indicated that they expressed not only the
endothelial cell markers CD34, CD31, VEGFR2 and VE-cadherin
but also the myeloid cell marker CD14 (Kalka et al, 2000).
FUNCTIONAL EVIDENCE FOR THE BONE MARROW
COMPONENT OF ADULT ANGIOGENESIS
Striking evidence supporting the existence of a bone marrow-
derived component of angiogenesis arose from studies of mice
with mutations in the Id family of transcriptional repressors.
Id1þ/ Id3 /  mice exhibited defects in postnatal angiogenic
sprouting and suppressed tumour growth (Lyden et al, 2001).
However, tumours grew normally in Id mutant mice transplanted
with bone marrow from the wild-type mice. The vasculature of
100% of tumours grown in Id mutant mice transplanted with Rosa
26 (LacZþ) bone marrow was LacZþ, demonstrating that much
of the vasculature originated from bone marrow (Lyden et al,
2001). The importance of Id genes in tumour angiogenesis was also
observed in PTENþ/  mice, which exhibit spontaneous lympho-
mas, uterine carcinomas, prostate intraepithelial neoplasias and
pheochromocytomas. Tumour angiogenesis and growth, but not
incidence, was suppressed in PTENþ/ Id1þ/ Id3 /  mice
(Ruzinova et al, 2003). Transplantation of PTENþ/ Id1þ/
 Id3 /  mice with Rosa 26 bone marrow promoted tumour
angiogenesis and indicated that different tumours recruited bone
marrow-derived endothelial cells at different rates. While 16% of
the vasculature in uterine carcinomas derived from the bone
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that different tumours recruit bone marrow-derived cells to
different degrees (Ruzinova et al, 2003).
Additional evidence supporting the concept of bone marrow-
derived EPCs has been garnered from mouse bone marrow
transplantation models. In mice, bone marrow-derived progenitor
cells are c-kitþ cells that are deficient in expression of lineage
markers (Lin ). For example, GFPþLin  progenitor cells
isolated from GFPþ mice have given rise to GFPþ retinal blood
vessels when injected intravitrally into neonatal mice (Otani et al,
2002). Importantly, transplantation of single Lin-Sca1þGFPþ
bone marrow-derived cells into mice not only generated GFPþ
cells of all haematopoietic lineages but also GFPþ endothelial cells
in angiogenic tissues (Grant et al, 2002).
More evidence for the bone marrow-derived EPC has arisen
from studies on human CD34þ progenitor cells. Bone marrow-
derived CD34þ progenitor cells include haematopoietic short-
and long-term repopulating stem cells and partially committed
progenitor cells of the myeloid/erythroid and lymphoid lineages.
While CD34þ cells comprise a small percentage of the total
circulating white blood cell population (0.1%), angiogenic growth
factors and other chemokines such as GM-CSF induce significant
release of these cells from the bone marrow into the circulation.
Isolation of these cells by immune selection techniques has
permitted a number of studies that have shown that purified
CD34þ progenitor cells can promote angiogenesis and stimulate
tissue repair in vivo. In one key study, CD34þ stem cells were
used to promote neurogenesis after stroke in animal models.
Surprisingly, rather than directly stimulating neurogenesis,
CD34þ cells promoted angiogenesis, indirectly improving neu-
ronal function (Taguchi et al, 2004).
Analyses of human sex-mismatched bone marrow transplanta-
tion patients provided evidence that endothelial cells do arise from
bone marrow in humans. In one study, a small percentage of
vasculature of sex-mismatched transplant patients was derived
from the transplanted bone marrow. When patients were analysed
on average 1 year after transplantation, 2% of all endothelial arose
from the donor bone marrow (Jiang et al, 2004). In another study
of human sex-mismatched bone marrow transplant recipients who
later developed tumours, fluorescence in situ hybridisation
analysis showed that approximately 5% of endothelial cells
infiltrating tumours were derived from bone marrow (Peters
et al, 2005). Thus, experimental and clinical data confirm the
existence of bone marrow-derived endothelial progenitors.
RELATIONSHIP TO DEVELOPMENTAL
ANGIOGENESIS
A common precursor for haematopoietic and endothelial cells, the
hemangioblast, was first described by developmental biologists.
Endothelial cells and haematopoietic cells both arise in the blood
islands of the yolk sac, in the ventral wall of the aorta and in the
aorta–gonal–mesonephros region of the embryo. In vitro studies
of embryoid body formation from embryonic stem cells show that
both endothelial cells and haematopoietic cells arise from Flk-1þ
(VEGFR2) colonies (Choi et al, 1998). Additionally, embryonic
deletion in mouse of the transcription factor Scl/Tal1 suppresses
haematopoiesis, while knockdown of Scl in zebrafish inhibits
vascular development (Patterson et al, 2005). Mice deficient in the
AML-1 gene exhibit defective haematopoiesis and embryonic
lethality. In vitro studies of para-aortic splanchnopleural explants
showed that AML-1-deficient mice also exhibit defective vascular
development (Takakura et al, 2000). Together with evidence that
developing endothelial cells and haematopoietic cells arise from a
single common precursor CD31þVEGFR2þVE-cadherinþ
CD45  (Wang et al, 2004), these studies indicate that endothelial
cells and haematopoietic cells arise from a common precursor.
Importantly, embryonic EPCs (c-kitþSca1þFlk
lowTie2þ) have
been shown to give rise to tumour vasculature when injected into
adult mice undergoing tumorigenesis (Vajkoczy et al, 2003).
In postnatal animals, proliferating endothelial cells and haema-
topoietic progenitor cells also share certain surface determinants.
Both are CD34þVEGFR2þ cells that also express integrins a4b1
and a5b1. In fact, transplantation of a single GFPþ haematopoie-
tic precursor cell in mice resulted in mice with GFPþ
haematopoietic cells and GFPþ endothelial cells in angiogenic
tissues (Grant et al, 2002). These studies suggest that postnatal
hemangioblasts not only exist but can also be isolated and used to
repopulate either endothelial or haematopoietic lineages.
CHARACTERISATION OF EPCS BY MARKER
ANALYSIS
Many recent studies support the existence of a postnatal bone
marrow-derived endothelial precursor cell, the hemangioblast. Yet,
the exact nature of this cell type remains unclear. The first EPCs
were described as CD34-enriched mononuclear cells that acquired
endothelial surface marker expression in culture (Asahara et al,
1997). Subsequent studies showed that a subpopulation of
circulating CD34þ cells expressing CD34þCD133þVEGFR2þ
could form endothelial colonies in vitro (Peichev et al, 2000;
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Figure 1 Bone marrow-derived endothelial progenitor cells (EPCs)
contribute to tumour angiogenesis. Endothelial progenitor cells (purple
circles) arise in the bone marrow as CD34þCD133þVEGFR2þ cells.
These cells are induced to leave the bone marrow and enter the
vasculature by circulating angiogenic factors such as vascular endothelial
growth factor (VEGF). Once in the circulation, these cells can arrest at sites
of ischaemia or growth factor release (such as VEGF release), such as in the
tumour periphery. These cells then can participate in new vessel formation
by differentiating into branching blood vessels.
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CD14þ mononuclear cells give rise to endothelial cell-like colonies
in vitro or in vivo (Fujiyama et al, 2003; Gulati et al, 2003; Rehman
et al, 2003; Yang et al, 2004; Chavakis et al, 2005; Urbich et al,
2005). Thus, it appears that endothelial-like cells can arise from
within bone marrow-derived haematopoietic progenitor cell
populations (CD34þ cells) or monocyte populations (CD14þ or
CD11bþ cells). The actual identity of the endothelial precursor
may cross the boundaries of the stem cell and monocyte
populations (Schmeisser et al, 2001). A recent study showed that
CD34þ CD11bþ cells from cord blood yielded endothelial
colonies (Hildbrand et al, 2004). Thus, human endothelial cell
precursors may express both progenitor cell markers (CD34,
CD133), monocyte markers (CD14 and or CD11b) and endothelial
markers (VEGFR2). Interestingly, gene expression analysis compar-
ing EPCs to endothelial cells indicated that human endothelial cell
precursors closely resemble freshly isolated endothelial cells from
tumours rather than cultured endothelial cells (Bagley et al, 2003).
In studies from mice, endothelial precursor cells have derived
from Lin  cells or from Lin-Sca1þc-kitþ subpopulation of bone
marrow mononuclear cells. Some variability has been observed in
the in vivo contribution of EPCs to angiogenesis in mice, leading to
scepticism about the importance of this aspect of angiogenesis.
However, Shaked et al (2005) recently showed that different strains
of mice exhibit vastly different levels of circulating EPCs. These
results suggest that some of the different estimates of EPC
contributions to angiogenesis may be due to intrinsic strain or
tissue recruitment capabilities.
Many studies on the roles of bone marrow-derived angiogenesis
have been performed in FVB/N mice transplanted with Tie2LacZ
bone marrow (Asahara et al, 1997, 1999; Lyden et al, 2001). Tie2 is
best known as an endothelial cell marker; however, this protein
can be expressed by monocytes that may contribute to angiogen-
esis by secreting growth factors. In fact, at least one recent study
suggested that many of the Tie2 expressing bone marrow-derived
cells in angiogenic tissues are not endothelial precursor cells but
rather F4/80, CD11b-positive monocytes (de Palma et al, 2003).
However, these studies differed from previous studies by
transfecting bone marrow-derived progenitor cells with lentiviral
vectors expressing GFP under control of a Tie2 promoter. It is
possible that differences in mouse strains or technical methodol-
ogy accounts for the absence of Tie2-positive endothelial cells in
the de Palma studies.
Some of the variability in the characterisation of EPCs may arise
as a result of different purification methods. Originally, EPCS were
isolated by enriching for CD34þ cells and culturing in endothelial
growth medium on fibronectin-coated substrates (Asahara et al,
1997). Further studies with CD34þ cells purified by immunoaffinity
chromatography showed that these cells had long-term potential to
form endothelial cell-like colonies in vitro.H o w e v e r ,s o m eE P C s
have been isolated by culturing bone marrow-derived mononuclear
cells on fibronectin-coated plates for several days. These cells form
blood island-like colonies in vitro and some of these CD34 
populations have been shown to give rise to EPCs. Continued
pursuit of the identity of the EPC and study of its differentiation and
longevity will clarify the current discrepancies within the field.
REGULATION OF EPC RECRUITMENT
A number of growth factors and chemokines promote postnatal
angiogenesis. Best characterised of these is VEGF. During tumour
angiogenesis or after ischaemic injury, the level of circulating
VEGF have been shown to rise (Senger et al, 1986; Connolly et al,
1989; Leung et al, 1989). This increased circulating VEGF promotes
the mobilisation of EPCs from the bone marrow (Asahara et al,
1999; Hattori et al, 2001). In contrast, Ang-1 inhibited EPC release
from bone marrow (Hattori et al, 2001). Most recently, the novel
growth factor PDGF-CC was shown to promote revascularisation
of ischaemic tissues in part by stimulating outgrowth of
CD34þCD133þ EPCs (Li et al, 2005).
THERAPEUTIC AND PROGNOSTIC POTENTIAL
One of the greatest hopes for the study of endothelial progenitors is
their potential use in the therapy of ischaemic disease (Jain and
Duda, 2003). Soon after their discovery, endothelial progenitors
were used in attempts to restore blood flow to animals with
hindlimb ischaemia (Asahara et al, 1997, 1999). In these studies,
adoptive transfer of EPCs promoted restored blood flow and
increased capillary density, resulting in decreased loss of limbs
(Kalka et al, 2000). Further studies showed that introduction of
EPCs by intracardiac catheter promoted recovery from myocardial
ischaemia (Kawamoto et al, 2002). On the basis of these and other
similar studies, clinical pilot studies were performed to investigate
the use of EPCs in the restoration of blood flow in patients with
hearts that have been damaged by ischaemia (reviewed by Losordo
and Dimmeler, 2004). In the Transplantation of Progenitor Cells
and Regeneration Enhancement in Acute Myocardial Infarction
(TOPCARE-AMI) trial, patients received infusions of bone marrow-
derived mononuclear cells or EPCs approximately 4 days after
myocardial infarction. Patients receiving either population of cells
exhibited improved ejection fraction and end-systolic volumes,
indicating improved cardiac function. Several other clinical studies
showed similar effects (reviewed by Losordo and Dimmeler, 2004).
Recent studies suggest that enumeration of circulating EPCs in
patients may be useful in predicting the outcome of therapy or
disease course (Bertolini et al, 2003; Schmidt-Lucke et al, 2005).
Studies in mice indicate that the number of circulating EPCs is
affected by systemic exposure to angiogenic regulators such as
VEGF and can decline in response to antiangiogenic therapy such
as anti-VEGFR2 antibody therapy (Shaked et al, 2005). Che-
motherapeutic drug response can be measured in part by the level
of EPCs in circulation (Bertolini et al, 2003). Thus, measurement of
circulating EPCs may provide a useful assessment of disease
susceptibility or to response to therapies.
CONCLUSIONS
The field of angiogenesis research was revolutionised 8 years ago,
with the discovery of the circulating EPC. Since then, the nature of
this cell type and its abilities to form endothelial cell colonies in
vitro and in vivo have been studied. In vivo clinical studies have
been initiated to determine the potential of these cells to stimulate
tissue repair after ischaemic injury. While the exact subpopulation
of bone marrow-derived cells that can give rise to endothelial
colonies has not been identified, studies suggest that
CD34þCD11bþ cells contain these precursor cells. Improved
purification of these progenitor cells and continued study of their
long-term potential to generate endothelial cells in vivo will clarify
this embryonic field of vascular research.
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